Abstract
Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential ‘antioxidant’ activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.
Keywords: Glucagon-like peptide-1, oxidative stress, diabetes, diabetic complications.
Current Diabetes Reviews
Title:Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
Volume: 12 Issue: 4
Author(s): Karen Ekkelund Petersen, Günaj Rakipovski, Kirsten Raun and Jens Lykkesfeldt
Affiliation:
Keywords: Glucagon-like peptide-1, oxidative stress, diabetes, diabetic complications.
Abstract: Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential ‘antioxidant’ activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.
Export Options
About this article
Cite this article as:
Petersen Ekkelund Karen, Rakipovski Günaj, Raun Kirsten and Lykkesfeldt Jens, Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies, Current Diabetes Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573399812666150918150608
DOI https://dx.doi.org/10.2174/1573399812666150918150608 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Combined Transcriptomic and Proteomic Analyses of Cerebral Frontal Lobe Tissue Identified RNA Metabolism Dysregulation as One Potential Pathogenic Mechanism in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Current Neurovascular Research Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Antidiabetic Potential of Naturally Occurring Sesquiterpenes: A Review
Current Topics in Medicinal Chemistry The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) The Role of Inflammation in Neurological Disorders
Current Pharmaceutical Design Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research Anti-Vascular Endothelial Growth Factor Drug Treatment of Diabetic Macular Edema: The Evolution Continues
Current Diabetes Reviews Conference Report: 9th International Summer School of Neurology
CNS & Neurological Disorders - Drug Targets A Novel UPLC-MS/MS Method for the Determination of Salvianolic Acid A in Rat Urine, Feces, and Bile and its Application to Excretion Study
Current Pharmaceutical Analysis Network Pharmacology and Molecular Docking Approaches to Investigating the Mechanism of Action of <i>Zanthoxylum bungeanum</i> in the Treatment of Oxidative Stress-induced Diseases
Combinatorial Chemistry & High Throughput Screening The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology